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　A 67-year-old man was admitted to our hospital presenting with a liver injury. He had used several types of oral 
medication for the prior 2 years, including rosuvastatin calcium for hypertension, hyperlipidemia, and prostatic 
hypertrophy. His liver dysfunction was noted for the first time in February 2013, and at re-examination in March 2013 
he showed exacerbation of the liver dysfunction, he was admitted to our hospital at that time. We stopped all of his 
oral medications, and his liver function improved steadily. We conducted a drug-induced lymphocyte transformation 
test (DLST), and the rosuvastatin calcium result was positive. He was diagnosed as having a drug-induced (by 
rosvastatin calcium) liver injury. He resumed oral medications other than rosuvastatin calcium from the time of 
discharge, with no exacerbation of liver dysfunction since then. Reports of drug-induced liver injury due to drugs with 
a long-term oral administration are extremely rare. We discuss the relevant literature herein.
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2010/10 2011/７ 2011/11 2012/７ 2013/２
AST (U/L)  22  22  24  24 　235
ALT (U/L)  27  30  29  35 　235
ALP (U/L) 154 140 164 189 　597
LDH (U/L) 176 185 174 181 　312









入院時検査所見（表２）：AST 292U/L，ALT 605U/L とト
ランスアミナーゼの上昇を認め，総ビリルビン1.71㎎/ﾉ，















































<Hematology> ZTT 7.2 U/L <Virus>
WBC 4,400 /ﾒ CRP 0.78 ㎎/ﾉ HBs Ag ( － )
RBC 432×104 /ﾒ BUN 24 ㎎/ﾉ HBV-DNA ( － )
HGB 14.6 ℊ/ﾉ Creatinine 0.81 ㎎/ﾉ HCV Ab ( － )
PLT 21.5×104 /ﾒ Na 140 mEq/L HAV-lgM Ab ( － )
<Coagulation> K 4.2 mEq/L HEV-lgA Ab ( － )
PT-% 114 % Cl 104 mEq/L EB-VCA lgG 320×
PT-INR 0.95 BS 118 ㎎/ﾉ EB-VCA lgM ＜10×
<Blood Chemistry> TG 118 ㎎/ﾉ EBNA 20×
T.Protein 7.4 ℊ/ﾉ T-Chol 243 ㎎/ﾉ CMV lgG ( ＋ )
Albumin 3.8 ℊ/ﾉ HDL-Chol 90 ㎎/ﾉ CMV lgM ( － )
T.Bil 1.71 ㎎/ﾉ <Autoantibody>
D.Bil 1.0 ㎎/ﾉ lgG 1,336 ㎎/ﾉ
AST 292 U/L lgA 221 ㎎/ﾉ
ALT 605 U/L lgM 110 ㎎/ﾉ
LDH 292 U/L ANA ＜40×
ALP 1,287 U/L AMA ＜10×
γ-GTP 2,742 U/L TSH 2.21 μlU/ﾊ
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